Research and Markets (http://www.researchandmarkets.com/research/ae82e3/tuberculosis_infec) has announced the addition of GlobalData's new report "Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018" to their offering.
GlobalData, the industry analysis specialist, has released its new report, Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Tuberculosis (TB) infection market. The report identifies the key trends shaping and driving the market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global TB infection sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
The Tuberculosis Infection Market is Forecast to Decline Until 2018
The global Tuberculosis (TB) infection market was worth $38.3m in 2010. It is expected to decline at a Compound Annual Growth Rate (CAGR) of 4.5% during the next eight years to reach $26.6m by 2018. The TB drugs market has been well served by antimycobacterial agents and antibiotics since the 1960s. Cure rates have been improved with the conventional Directly Observed Therapy (DOTS). Multi-Drug Resistant Tuberculosis (MDR-TB) was a consequence of patient non-compliance and the long duration of therapy. Companies are actively developing products for the prophylaxis and cure of TB with shorter treatment durations. Two not-for-profit organizations - TB Alliance and the Aeras Global TB Vaccine Foundation - partnered with pharmaceutical players to develop novel therapies and vaccines that can provide better patient compliance and prevention against TB. However, the global TB drugs market is likely to decline as no launches are expected until 2018.
Companies Mentioned:
For more information visit http://www.researchandmarkets.com/research/ae82e3/tuberculosis_infec.
BusinessWire